Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PharmaTher announces positive topline results from clinical study of ketamine for Parkinson's Diseas

Stockhouse Editorial
2 Comments| March 24, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargePharmaTher Holdings Ltd. (CSE.PHRM) – a psychedelics biotech company focused on the development and commercialization of specialty ketamine pharmaceuticals for mental health, neurological, and pain disorders – announce positive topline results from the dose-finding and tolerability clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

The study results are adequate to give an effect size in powering a Phase 3 clinical study, which is expected to bridge the design with increased treatment duration relative to the Company’s Phase 2 clinical study.

Click here for full press release.


New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today